Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

Creative Medical Technology Holdings buys 80% of BioDefense from affiliate CAC

Neutral Impact 3 of 5 m&a Written later

Creative Medical Technology Holdings (CELZ) agreed on September 24, 2026 to buy 4,000,000 BioDefense common shares from Creative Acquisition Corp. (CAC), a company controlled by CEO Timothy Warbington. The company paid $200,000 in cash and 1,000,000 of its own common shares, raising its stake in BioDefense to 80%, which is a related-party transaction shareholders should weigh.

Key points

  • Purchase of 4,000,000 BioDefense shares from CAC for $200,000 in cash plus 1,000,000 CELZ common shares
  • After the deal, CELZ owns 16,000,000 BioDefense shares (80%) and CAC owns 4,000,000 (20%)
  • CEO Timothy Warbington is Chairman and CEO of CAC and indirectly owns all of its shares
  • The 1,000,000 CELZ shares were issued to CAC in a private placement under Section 4(a)(2) of the Securities Act

The filing

CompanyCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Form8-K, current report
Filed with the SECSep 25, 2026, 5:00 PM ET
Accession number0001477932-26-005805

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.